JP7082616B2 - 医薬化合物 - Google Patents
医薬化合物 Download PDFInfo
- Publication number
- JP7082616B2 JP7082616B2 JP2019520591A JP2019520591A JP7082616B2 JP 7082616 B2 JP7082616 B2 JP 7082616B2 JP 2019520591 A JP2019520591 A JP 2019520591A JP 2019520591 A JP2019520591 A JP 2019520591A JP 7082616 B2 JP7082616 B2 JP 7082616B2
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- imidazol
- dimethyl
- mmol
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1617627.3 | 2016-10-18 | ||
| GBGB1617627.3A GB201617627D0 (en) | 2016-10-18 | 2016-10-18 | Pharmaceutical compounds |
| PCT/GB2017/053153 WO2018073587A1 (en) | 2016-10-18 | 2017-10-18 | Pharmaceutical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535658A JP2019535658A (ja) | 2019-12-12 |
| JP2019535658A5 JP2019535658A5 (enExample) | 2020-11-26 |
| JP7082616B2 true JP7082616B2 (ja) | 2022-06-08 |
Family
ID=57680679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520591A Active JP7082616B2 (ja) | 2016-10-18 | 2017-10-18 | 医薬化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10647704B2 (enExample) |
| EP (1) | EP3529240B1 (enExample) |
| JP (1) | JP7082616B2 (enExample) |
| CN (1) | CN110036002B (enExample) |
| AU (1) | AU2017346454B2 (enExample) |
| DK (1) | DK3529240T3 (enExample) |
| ES (1) | ES2824814T3 (enExample) |
| GB (1) | GB201617627D0 (enExample) |
| HU (1) | HUE052107T2 (enExample) |
| WO (1) | WO2018073587A1 (enExample) |
| ZA (1) | ZA201902335B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| TW202102494A (zh) | 2019-03-15 | 2021-01-16 | 美商弗瑪治療公司 | 抑制環amp-反應元件-結合蛋白(creb) |
| CN112574189B (zh) * | 2019-09-27 | 2024-05-31 | 海创药业股份有限公司 | 一种ep300/cbp抑制剂 |
| CN112574191B (zh) * | 2019-09-29 | 2024-01-23 | 南京圣和药业股份有限公司 | 异噁唑杂环类化合物及其应用 |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| TW202227429A (zh) * | 2020-11-06 | 2022-07-16 | 大陸商貝達藥業股份有限公司 | Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法 |
| CN116670129A (zh) * | 2020-12-31 | 2023-08-29 | 南京明德新药研发有限公司 | 苯并咪唑类化合物及其应用 |
| CN114989158A (zh) * | 2021-03-02 | 2022-09-02 | 复旦大学 | 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用 |
| CN117645603A (zh) * | 2022-09-05 | 2024-03-05 | 复旦大学 | p300溴结构域抑制剂及其药用组合物及其应用 |
| KR20250113346A (ko) | 2024-01-17 | 2025-07-25 | 주식회사 엘지화학 | CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물 |
| TW202542135A (zh) | 2024-01-17 | 2025-11-01 | 南韓商Ｌｇ化學股份有限公司 | 作為ＣＢＰ／ｐ３００抑制劑之新穎化合物和含有彼作為活性成分以預防或治療癌症、發炎病症或自體免疫疾病之醫藥組成物 |
| CN122535608A (zh) | 2024-01-17 | 2026-08-07 | 株式会社Lg化学 | 用作cbp/p300抑制剂的新型化合物以及包含其作为活性成分的用于预防或治疗癌症、炎性障碍或自身免疫性疾病的药物组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004030625A2 (en) | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Synergistic methods and compositions for treating cancer |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| WO2018073586A1 (en) | 2016-10-18 | 2018-04-26 | Cellcentric Ltd | Pharmaceutical compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070129353A1 (en) * | 2005-11-08 | 2007-06-07 | Michael Kahn | Alpha-helix mimetics and method relating to the treatment of cancer stem cells |
| US8501957B2 (en) | 2008-12-10 | 2013-08-06 | China Medical University | Benzimidazole compounds and their use as anticancer agents |
| US9005670B2 (en) * | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| EP2397471A1 (en) | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| CN105473581B (zh) * | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| CA2966452A1 (en) | 2014-12-17 | 2016-06-23 | Samuel David Brown | Substituted bicyclic compounds as bromodomain inhibitors |
| GB201506658D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
-
2016
- 2016-10-18 GB GBGB1617627.3A patent/GB201617627D0/en not_active Ceased
-
2017
- 2017-10-18 EP EP17790814.2A patent/EP3529240B1/en active Active
- 2017-10-18 WO PCT/GB2017/053153 patent/WO2018073587A1/en not_active Ceased
- 2017-10-18 DK DK17790814.2T patent/DK3529240T3/da active
- 2017-10-18 CN CN201780072397.7A patent/CN110036002B/zh active Active
- 2017-10-18 HU HUE17790814A patent/HUE052107T2/hu unknown
- 2017-10-18 US US16/341,650 patent/US10647704B2/en active Active
- 2017-10-18 ES ES17790814T patent/ES2824814T3/es active Active
- 2017-10-18 AU AU2017346454A patent/AU2017346454B2/en active Active
- 2017-10-18 JP JP2019520591A patent/JP7082616B2/ja active Active
-
2019
- 2019-04-12 ZA ZA2019/02335A patent/ZA201902335B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004030625A2 (en) | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Synergistic methods and compositions for treating cancer |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| WO2018073586A1 (en) | 2016-10-18 | 2018-04-26 | Cellcentric Ltd | Pharmaceutical compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201617627D0 (en) | 2016-11-30 |
| EP3529240B1 (en) | 2020-08-05 |
| US10647704B2 (en) | 2020-05-12 |
| ZA201902335B (en) | 2024-11-27 |
| EP3529240A1 (en) | 2019-08-28 |
| US20190263788A1 (en) | 2019-08-29 |
| HUE052107T2 (hu) | 2021-04-28 |
| AU2017346454B2 (en) | 2022-02-17 |
| AU2017346454A1 (en) | 2019-05-02 |
| CA3039643A1 (en) | 2018-04-26 |
| WO2018073587A1 (en) | 2018-04-26 |
| ES2824814T3 (es) | 2021-05-13 |
| DK3529240T3 (da) | 2020-09-07 |
| NZ752356A (en) | 2025-02-28 |
| CN110036002A (zh) | 2019-07-19 |
| CN110036002B (zh) | 2022-08-30 |
| JP2019535658A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3529240B1 (en) | Pharmaceutical compounds | |
| US11377443B2 (en) | Pharmaceutical compounds | |
| JP6871864B2 (ja) | イソオキサゾリル置換ベンズイミダゾール類 | |
| EP3286188B1 (en) | Isoxazolyl substituted imidazopyridines | |
| JP7553450B2 (ja) | ユビキチン特異的プロテアーゼ１を阻害するための組成物 | |
| RU2629194C2 (ru) | Производные 1,5- и 1,7-нафтиридина, полезные при лечении заболеваний, опосредованных fgfr | |
| JP2022529616A (ja) | 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体 | |
| HUE028967T2 (en) | Kinozalin carboxamide azetidines | |
| CA3039643C (en) | Benzimidazoles and use thereof as modulators of p300 and/or cbp activity | |
| HK40005627A (en) | Pharmaceutical compounds | |
| HK40005627B (en) | Pharmaceutical compounds | |
| EP4393908A1 (en) | Bis-pyrazolyl-methane compounds affecting kras | |
| BR112019007834B1 (pt) | Compostos farmacêuticos | |
| EA041318B1 (ru) | Арилимидазолилизоксазолы и их применение | |
| HK40006202A (en) | Pharmaceutical compounds | |
| HK40006202B (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190704 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201014 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220517 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220527 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7082616 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |